Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Sarepta Therapeutics Inc (SRPT) USD0.0001

Sell:$73.41 Buy:$73.54 Change: $3.51 (5.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $3.51 (5.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $3.51 (5.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Contact details

215 1st St Ste 415
United States
+1 (617) 2744000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$5.51 billion
Shares in issue:
79.42 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • M. Kathleen Behrens
    Independent Chairwoman of the Board
  • Douglas Ingram
    President, Chief Executive Officer, Director
  • Ian Estepan
    Chief Financial Officer, Executive Vice President, Principal Accounting Officer
  • William Ciambrone
    Executive Vice President - Technical Operations
  • Alexander Cumbo
    Executive Vice President and Chief Commercial Officer
  • Gilmore O'Neill
    Executive Vice President, R&D and Chief Medical Officer
  • Louise Rodino-Klapac
    Chief Scientific Officer
  • Ryan Brown
    Interim General Counsel
  • Dallan Murray
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.